论文部分内容阅读
应用CTL/胸腺肽复合免疫疗法 ,对 7例恶性黑色素瘤 (恶黑 )患者 ( 6例为单侧眼球切除术后 ,1例为宫颈多发恶黑术后 )经 5个疗程的治疗 ,其中宫颈多发恶黑患者由于出现血性腹水 ,对其进行 2次TIL/胸腺肽治疗。经 2个疗程治疗后 7例患者癌胚抗原全部转为阴性 ,IL 2分泌活性与治疗前及正常人比较有程度不同的升高。通过追踪观察 ,7例患者 1例死亡 (宫颈多发恶黑 ) ,1例出现淋巴结转移 ,其中 1例已存活 5年 ,1例已存活 4年 ,3例已存活 3年。与临床统计数值比较证明 ,CTL/胸腺肽和TIL/胸腺肽复合免疫治疗可以提高恶性黑色素瘤患者的免疫功能 ,降低转移率 ,延长患者的生命
CTL/thymosin peptide complex immunotherapy was used to treat 7 cases of malignant melanoma (black) patients (6 cases after unilateral excision of the eyeball and 1 case after cervix complications) after 5 courses of treatment, including multiple cervix Patients with severe black blood were treated with TIL/thymosin 2 times due to bloody ascites. After the two courses of treatment, carcinoembryonic antigens were all negative in 7 patients, and the IL 2 secretion activity was significantly different from that before treatment and normal people. Through follow-up observations, 7 patients died of 1 case (cervical multiple cases of darkness) and 1 case had lymph node metastases. One case had survived for 5 years, 1 case had survived for 4 years, and 3 cases had survived for 3 years. Compared with clinical statistics, CTL/thymosin and TIL/thymosin combined immunotherapy can improve the immune function of patients with malignant melanoma, reduce the metastasis rate, and prolong the patient’s life.